ABSTRACT Background: Although diabetes mellitus (DM) is often associated with painful neuropathic syndromes, a signifi cant number of DM patients suff er from non-neuropathic (nociceptive) pain. Unfortunately, there is insuffi cient data on the epidemiology of nociceptive pain in DM patients and its eff ect on their quality of life. Objective : To characterize pain in type 2 DM patients, and assess its eff ect on their quality of life. Methods: The study population included 342 type 2 DM patients, 18 years of age and above (mean age 70.7 Ϯ 9.7), who reported having pain. The study questionnaires included the Brief Pain Inventory (BPI), the S-LANSS scale to assess pain with neuropathic features, life impact, and socio-demographic data. Results: One hundred and fi fty-fi ve DM patients (46.5%) reported having pain of predominantly neuropathic origin. Almost 75% of patients with neuropathic pain were females, compared to 57.8% of patients with nociceptive pain ( P ϭ 0.002). More patients with neuropathic pain reported constant daily pain (57.6% vs. 42.4%, P Ͻ 0.0001), and worse pain during the night (53.3% vs. 46.7%, P ϭ 0.045). The pain aff ected daily activities, walking capacity, and mood. Patients with neuropathic pain reported a greater negative eff ect of pain on their quality of life than those with nociceptive pain (41.0% vs. 15.3%, P Ͻ 0.0001).
INTRODUCTION
The prevalence of diabetes mellitus (DM) in developed countries has increased signifi cantly over recent decades. In the year 2000, the prevalence was estimated to be 8.6% among individuals 20 years of age and above, and as high as 20.1% among individuals 65 years of age and older (1). According to the latest estimates of the International Diabetes Federation in 2012, there were more than 371 million people with DM. By 2030, this number is expected to reach 552 million (2).
Various pain syndromes are associated with DM and are an integral part of the disease, contributing to its morbidity and aff ecting patients ' quality of life. One of the well-recognized pain types is painful diabetic neuropathy (3). This is a debilitating disorder that occurs in nearly 50% of DM patients (4). However, other types of chronic non-neuropathic pain syndromes, such as frozen shoulder and abdominal pain, have been reported (5).
The eff ect of DM on the musculoskeletal system has received signifi cantly less research attention than its eff ect on the heart, brain, kidneys, eyes and nerves. Vascular changes in both small and large vessels and metabolic changes related to high blood glucose levels aff ect the musculoskeletal system. The prevalence of musculoskeletal pain is higher in DM patients than in the general population (6).
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The goal of this study was to characterize pain syndromes in type 2 DM patients and assess the eff ect of pain on patients ' quality of life.
METHODS

Study design
The national health insurance system, implemented in Israel in 1995, provides healthcare to the entire population through non-profi t health maintenance organizations ( ' sick funds ' ). The Clalit Health Services, the largest HMO in Israel, insures about 55% of the Israeli population.
Selection of study subjects
The study population consisted of type 2 DM patients, 18 years of age and above, from four primary care clinics of the Clalit Health Services in the Negev region of Israel. The study population included 2251 type 2 DM patients listed in the four primary care clinics. Patients who agreed to participate were interviewed by nurses by telephone using a structured questionnaire. The interviews were conducted during the years 2006 -2009. Only patients who reported pain, of any type, were included in the study.
The Helsinki Committee (IRB) of the Soroka University Medical Center approved the study (approval No. 4310) .
Measurements and outcomes
Study questionnaires included:
The Brief Pain Inventory-Short Form (BPI-SF) was (a) used to measure and characterize pain and its interference with the patients ' lives (reactive dimension). The BPI questionnaire includes a rating scale of 0 to 10 to measure pain and the eff ect of pain on diff erent aspects of daily life (general activity, mood, sleep, relationships with others, and work). This tool was validated in Hebrew for a previous study (7) and has been used as an outcome measure in various clinical trials (8,9). The ' life impact ' variable was calculated as the mean of items relating to the eff ect of pain on life activities. The S-LANSS Pain Scale self-report version is a (b) self-report instrument for identifying neuropathic pain. Its aims are to identify pain of predominantly neuropathic origin, as distinct from nociceptive pain, without the need for clinical examination (10). The S-LANSS is a simple seven-item tool. Each item entails a binary response (yes or no) to the presence or absence of symptoms (fi ve items) or clinical signs (two items). A score of 12 or more suggests pain of predominantly neuropathic origin. In the present study, we used the term neuropathic pain for patients suff ering from pain of predominantly neuropathic origin. The questionnaires were translated from English to Hebrew using the backtranslation method (11) after which they underwent cultural adaptation. Socio-demographic data. (c)
The questionnaire also included questions relating to pain location and duration.
Statistical analyses
Statistical analyses were performed using the SPSS 17 software. Continuous variables are shown as means and standard deviations. Categorical variables are described as frequencies. T-tests and χ -square tests were used to analyse statistically signifi cant diff erences between neuropathic and nociceptive pain groups for continuous and categorical variables, respectively. As a result of missing data in the S-LANSS questionnaire, the total S-LANSS score could not be calculated for nine patients, and they were not included in the comparison between the neuropathic and nociceptive pain groups. Two-tailed P -values Ͻ 0.05 with a power of 80% were considered statistically signifi cant.
A logistic regression model was constructed to identify associations between patients ' characteristics and the presence of nociceptive pain. The conceptual framework was that age and gender would not be associated with the type of pain. We assumed that patients reported worse pain during the day and a lower eff ect of pain on daily activities would be reported by patients who suff er from nociceptive pain.
RESULTS
Study population
The study population included 2251 type 2 DM patients listed in the four primary care clinics. One hundred and sixteen (5.2%) refused to participate in the study; 253 (11.2%) did not speak Hebrew, 180 (8%) had a wrong telephone number listed, 94 (4.2%) were unable to answer a telephone questionnaire (due to mental/physical status), 1 212 (53.8%) could not be located by telephone after several attempts, and 396 (17.6%) agreed to participate in the study. Of the 396 patients who agreed to participate in the study, only 54 (13.6%) did not report any pain.
per cent of the DM patients suff ered from nociceptive pain. One hundred and fi fty-fi ve participants (46.5%) had neuropathic pain as determined by an S-LANSS score Ն 12. Most of these patients (61.4%) reported that the pain was accompanied by strange, unpleasant sensations on the skin like stabbing or tingling. These sensations suddenly appeared like a storm and were paroxysmal in nature. Fifty-fi ve per cent were hypersensitive or felt numbness.
Almost 75% of patients with neuropathic pain were women compared with 57.8% of patients with nociceptive pain ( P ϭ 0.002). No other statistically signifi cant differences were found in the socio-demographic characteristics of patients with neuropathic and nociceptive pain (Table 1) .
Characteristics of pain in DM patients
The BPI questionnaire was used to record the pain characteristics of the study population. Pain was located mainly in the limbs (45%), the back (20%), and the head and neck (13%). The average duration of pain was 77.7 Ϯ 117.6 months (range: 1 -816 months). Most patients (73.6%) reported having pain for more than 12 months. Patients who did not report pain were ineligible.
Characteristics of patients with neuropathic and nociceptive pain are presented in Table 2 . Constant daily pain was reported more by patients with neuropathic pain (57.6% vs. 42.4%, P Ͻ 0.0001). The worst pain was experienced during the night (53.3% vs. 46.7%, ϭ 0.045). One hundred and thirty-two patients (38.6%) stated that with nociceptive pain, were included in the model for adjustment. The independent variables found to be statistically signifi cant in the model were not having constant pain (OR ϭ 0.528, 95%CI: 0.322 -0.865, P ϭ 0.011) and lower impact of pain on daily activities (OR ϭ 0.783, 95%CI: 0.767 -0.919, P Ͻ 0.0001). The independent variable, the worst pain during the day, had a borderline statistical signifi cance (OR ϭ 1.629, 95%CI: 0.984 -2.696, P ϭ 0.058).
DISCUSSION
Main fi ndings
Almost half of DM patients reported having pain of predominantly neuropathic origin. Most of the patients (73.6%) reported having suff ered from pain for more than 12 months. Most patients with neuropathic pain were females.
More patients with neuropathic pain reported constant daily pain and worse pain during the night. The pain aff ected daily activities, walking capacity, and mood. Patients with neuropathic pain reported a greater negative eff ect of pain on their quality of life.
Interpretation of the study results
Neural injury that causes neuropathic pain in DM is well recognized and has been reported frequently in the literature while nociceptive pain has received less attention. Diabetes neuropathy aff ects up to 50% of patients DM was the source of their pain, and 33.3% thought there was no specifi c source.
Life impact index
The variable ' life impact ' was calculated as the mean for items in the BPI questionnaire relating to the eff ect of pain on life activities. The mean reported pain level was 6.3 Ϯ 2.5 on a scale from 0 to 10. The mean eff ect of pain on general daytime activity was 5.5 Ϯ 2.9. Pain aff ected mood (5.5 Ϯ 3.0) and the capacity to walk (5.5 Ϯ 3.1) to a similar degree. Only four of the participants (1.6%) did not report an association between pain and the Life Impact Index. Only 27.3% of patients reported a mild eff ect on quality of life while 45.1% reported a moderate eff ect, and 26.1% a severe eff ect. Patients with neuropathic pain reported a statistically signifi cant higher impact of pain on life activities in all aspects (Table 3 ). In univariate analyses there was no association between the Life Impact Index and age, occupation, family status, gender, education, country of birth, or religious belief.
Logistic regression model for predicting diabetes patients with nociceptive pain
A logistic regression model was developed to predict patients ' characteristics associated with features of nociceptive pain (Table 4 ). The dependent variable was nociceptive pain, determined by an S-LANSS questionnaire score Ͼ 12. The independent variables gender and age, which did not have a statistically signifi cant association a Due to missing data in the S-LANSS questionnaire nine patients were excluded.
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For personal use only. with DM (12). As observed in this study neuropathic pain has a signifi cant impact on function and quality of life in DM, and has a negative eff ect on patient ' s quality of life. In a study from Turkey, the prevalence of diabetic neuropathy, determined by clinical examination alone, was 40.4% and increased to 62.2% when nerve conduction studies were added to the clinical examination (13). A small study found that quality of life was signifi cantly on a scale of 0 -10. The pain aff ected daily activities in general, as well as mood and capacity to ambulate. Data collected in six European countries on neuropathic pain in DM, using the Short-form Brief Pain Inventory, found a mean pain level of 5.0 Ϯ 2.0, with a negative eff ect on employment in 35%. The severity of pain was associated signifi cantly with a decrease in the general health status, greater pain interference score, lower employment rates, and more physician visits (29). We found that only 1.6% did not report an association between pain and Life Impact Index. Among those who reported that pain did aff ect their lives, 71.2% reported that the eff ect was moderate or severe. More patients with neuropathic pain reported constant daily pain ( P Ͻ 0.0001) and more severe life impact index score ( P Ͻ 0.0001).
Strengths and limitations
We used the S-LANSS, a self-report instrument, to identify neuropathic pain. Neuropathic pain is defi ned as pain arising as a direct consequence of a lesion or disease aff ecting the somatosensory system either at the peripheral or central level. Screening questionnaires are suitable for identifying potential patients with neuropathic pain, but they require further validation for epidemiological purposes (30, 31) .
The study was conducted in a single geographical area, and a similar study in other areas of Israel or other countries may have yielded diff erent results. However, since DM and pain are worldwide conditions, we believe that our results are likely to refl ect the situation around the world.
Another study limitation is a potential selection bias related to the low response rate. Our study population included elderly patients interviewed by telephone. In the elderly population there is a high prevalence of pain. It is possible that those DM patients who were unable to answer the questionnaire may have suff ered from a higher prevalence of pain. If that is the case our fi ndings more impaired among patients with diabetic neuropathy than among patients without it. Patients with diabetic neuropathy had greater impairment in emotional reactions, energy, pain, physical mobility, and sleep (14). In a cross-sectional evaluation of function and healthrelated quality of life in patients with neuropathic pain, the pain intensity on a fi ve-point visual analogue scale was 2.8 Ϯ 1.0. Pain substantially interfered with normal work (5.9, 0 -10 scale), social activities (5.7), and family life (5.3) (15). Painful diabetic neuropathy was associated with decrements in many aspects of patients ' levels of physical and emotional functioning, and it aff ected symptoms and sleep. The negative impact was higher in patients with greater pain severity (16).
Musculoskeletal pain is more prevalent in DM patients than in the non-diabetic general population (6). The prevalence of frozen shoulder and shoulder joint adhesions ranges from 11 -20% among DM patients to 2 -10% in the healthy population (17, 18) . Limited joint function is reported to a range from 8 -50% in DM to 0 -26% in non-diabetics (19, 20) . Pain from local infl ammation of the palm tendons is ten times more prevalent in DM (21), and a similar ratio was found for carpal tunnel syndrome (22, 23) . Another typical pain syndrome in the palm is Dupuytren ' s contracture, which is also much more prevalent in DM patients (24, 25) . Degenerative changes in the vertebrae, as in other joints, is more common in DM. Diff use idiopathic skeletal hyperostosis is particularly prevalent in DM with an incidence rate that reaches 13 -49% compared to 1.6 -13% in non-diabetics (22, 26, 27) .
Over one third of the study population (37.6%) reported constant pain, particularly in the limbs, the back, and the head and neck. In another study that assessed the prevalence of chronic pain among CHS members in Israel, 46% of the participants reported chronic pain. Prevalent pain sites were the back (32%), limbs (17%) and head (13%) (28).
The mean pain severity reported in this study for any type of pain, neuropathic or nociceptive, was 6.3 Ϯ 2.5 regarding pain could be an underestimate of the real prevalence. Furthermore, since we used a telephone interview we were unable to locate many patients. Participation rates for epidemiological studies have declined over the past 30 years (32) . In a study that compared response rates for postal, Internet and telephone modes of recruitment the highest response rate was for telephone interviews and that was only 27.3% (273 of 1000 contacted) (33).
Implications
In DM patients reporting the same severity of pain, neuropathic pain has a greater negative eff ect than nociceptive pain. This is probably the reason that it has gained more attention in the medical literature. For this reason, neuropathic pain should be treated more aggressively.
Pain is an integral part of DM in many patients and has a signifi cant eff ect on their quality of life and daily function. Nociceptive pain is reported frequently by DM patients. This study, like others (34,35), shows a gap in the literature and highlights the need for greater awareness of the presence and eff ect of pain in type 2 DM patients in the primary care setting. This could contribute to a better understanding of painful DM and promote the development of more targeted and eff ective treatments.
Conclusion
Clinicians should be aware of the high prevalence of pain of any kind in type 2 DM. Neuropathic pain is constant, worse at night and has a signifi cant impact on daily activities. Decisions on appropriate pain management should be tailored to the nature of the pain (neuropathic or nociceptive).
Further research is needed to develop other eff ective treatment options for neuropathic and nociceptive pain in DM.
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